Therapeutic Asset Ratings
133 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Evorpacept
Her2-Receptor Negative Breast Cancer
QuantumLeap Healthcare Collaborative
P1
C
(37)
Fam-Trastuzumab Deruxtecan-Nxki
Her2-Receptor Negative Breast Cancer
QuantumLeap Healthcare Collaborative
P1
C
(37)
flt3 ligand
HER2-negative Breast Cancer
University of Texas Southwestern Medical Center
P1
C
(37)
her2 - primed dendritic cells
Her2-Receptor Negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
P1
C
(37)
her3 - primed dendritic cells
Her2-Receptor Negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
P1
C
(37)
Naptumomab Estafenatox
Her2-Receptor Negative Breast Cancer
NeoTX Therapeutics Ltd.
P1
C
(37)
Obinutuzumab
Her2-Receptor Negative Breast Cancer
NeoTX Therapeutics Ltd.
P1
C
(37)
Zn-C3
Her2-Receptor Negative Breast Cancer
Filipa Lynce, MD
P1
C
(37)
Showing 126 to 133 of 133 assets
Previous
Page 6 of 6
Next
